Point-and-click, model-informed drug discovery and development (MID3) software to assess efficacy, safety, and therapeutic index for early stage biotherapeutics.
Simulating pre-built models across a range of therapeutic modalities and disease areas helps inform target selection, project clinical dose requirements, design a lead optimization funnel, and identify areas of program risk.
Applied BioMath Assess™ offers several libraries of monospecific and bispecific, single compartment and multicompartment models covering common pharmacologies.
Biotherapeutic Model Pack
Applied BioMath Assess™ includes 18 models covering 9 common pharmacologies. Each pharmacology has a one-compartment model version and a four-compartment model version with monospecific and bispecific antibodies.
Cell Engager Model Pack
Models for solid tumors, in-vitro experiments, and solid tumors with 2 cell types.
Protein Degrader Model Pack
Includes 4 models covering in vivo and in vitro models of PROTAC and Molecular Glue Degrader pharmacologies.
Avidity Model Pack
An advanced biotherapeutic model pack that incorporates avid bivalent antibodies into many of the core biotherapeutic models.
Gene Therapy Model Pack
Models covering 8 LNP-encapsulated mRNA and siRNA therapies.
"Applied BioMath Assess enables me to quickly explore design hypotheses, and better understand tradeoffs between PK, Target Engagement, and TMDD of our bispecific antibodies. To be able to explore these variables in an interactive tool without having to program it from scratch is an immense time and resource saver for me. This is a powerful tool put directly in the hands of scientists."
"Applied BioMath Assess was an essential step for our portfolio prioritization. We had several therapeutics under consideration and needed to understand what parameter ranges were required to achieve our desired outcomes. Being able to quickly analyze each therapeutic helped us identify which therapeutics were best to pursue and ultimately helped us de-risk our portfolio and provide a clear and scientific rationale with our stakeholders."